Excess Morbidity Persists in Patients With Cushing’s Disease During Long-term Remission: A Swedish Nationwide Study
Eleni Papakokkinou(Sahlgrenska University Hospital), Óskar Ragnarsson(University of Gothenburg), Pia Burman(Malmö University), Charlotte Höybye(Karolinska University Hospital), Dimitrios Chantzichristos(Sahlgrenska University Hospital), Bertil Ekman(Linköping University), Sophie Bensing(Karolinska University Hospital), Elin Segerstedt(Umeå University), Gudmundur Johannsson(Sahlgrenska University Hospital), Jeanette Wahlberg(Örebro University), Tommy Olsson(Umeå University), Per Dahlqvist(University Hospital of Umeå), Erik Schwarcz(Örebro University), Katarina Berinder(Karolinska University Hospital), Lorenza Bonelli(Skåne University Hospital), Anna-Karin Åkerman(Örebro University), Eva Marie Erfurth(Skåne University Hospital), Daniel S Olsson(University of Gothenburg), Cecilia Follin(Lund University), Britt Edén Engström(Uppsala University), Maria Petersson(Karolinska University Hospital), Ing-Liss Bryngelsson(Örebro University Hospital), David Petranek(Skåne University Hospital)
Cited by 77
Related Papers
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
|New England Journal of Medicine|2000|874
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
|The Lancet|2001|643
Leptin is associated with increased risk of myocardial infarction
|Journal of Internal Medicine|1999|355
Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood Pressure<sup>1</sup>
|The Journal of Clinical Endocrinology & Metabolism|1997|335
Hypothalamic–Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society* Clinical Practice Guideline
|The Journal of Clinical Endocrinology & Metabolism|2018|216